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QUANTITATIVE ANALYSIS OF TETRAHYDROCANNABINOL FOR FORENSIC 
APPLICATIONS IN SEIZED DRUGS 
 
 
An Abstract of the Thesis by 
Jana Jo Gannaway 
 
 
 Cannabis and its’ associated psychoactive cannabinoid THC have become more popular 
within the public community. And with popularity comes the political, social, medical, and fiscal 
concerns associated with cannabis demands not only governmental scrutiny, but also rigorous 
research and scientific examination. The forensic community needs to be prepared and competent 
in every aspect. In order to demonstrate an exhaustive research and scientific analysis, a 
quantitative method was developed using an Agilent GCMS quadrupole as this is the main 
workhorse in many forensic drug laboratories. The internal standard tribenzylamine was initially 
chosen along with the drug standard THC. The calibration curve was linear with correlation a 
coefficient of 0.98 – 0.99, however the internal standard and drug standard began interacting with 
each other and degrading after approximately 2 weeks. A new internal standard, tetradecane, was 
chosen for its non-polar properties. Results with tetradecane proved to be very unreproducible. 
Quality control samples regularly did not pass their ± 20% accuracy requirement. Relative 
standard deviation of the internal standard ranged from 6.10-25.77%.  The limit of detection for 
both Agilent GCMS instruments was 0.1% THC on a total dry weight basis while the limit of 
quantitation was 0.4%. Relative standard deviation of the seized THC samples ranged 0-3.13%. 
Next, a quantitative method was developed using a Waters LC-UV-MS single quadrupole. A 5 
point calibration curve was used each day. Calibration curves were run on 3 different days. 
Standard calibration curves were linear with a correlation coefficient of 0.99 or above each day. 
The limit of detection was 0.0002% THC on a total dry weight basis while the limit of 
quantitation was 0.00085%. The GCMS detectors were not sensitive enough to quantitate the 




enough to be able to quantify the range of THC concentrations that are routinely seen in the 
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With the rise in public interest, it is vital for forensic laboratories to develop a method to 
quantify THC in raw cannabis vegetation. Depending on the application, cannabis can have a 
wide range of THC content. This requires a tremendous amount of work as quantifying THC is 
time and labor-intensive. It is important to be able to detect and distinguish a large THC 
concentration range. THC is the major psychoactive cannabinoid produced in varying parts of the 
plant. Most forensic laboratories struggle with a way to decrease or eliminate their backlog. An 
efficient and validated method for quantifying THC over a wide dynamic range is needed while 
keeping the maintenance on the instrument to a minimum. This will allow for the method to be 
thoroughly tested and meet SWGDRUG guidelines and standup within the criminal court 





















Cannabis and its products are the most widely consumed illicit drug in the United States 
as well as worldwide (UNODC 2009; Ruppel . 2009; Mehmedic 2010).  The psychoactive 
compound within the Cannabis species is called ∆9-tetrahydrocannabinol, commonly referred to 
as THC. It has been used for its euphoric effects on the central nervous system (CNS). There are 
various phenotypes of Cannabis. Phenotype I (drug type) has THC weight percent’s  ranging 
from 0.5-15%, phenotype II (intermediate type) has THC weight percent’s ranging from 0.5-5%, 
and phenotype III (fiber type) has THC weight percent’s ranging from 0.05-0.70% (Upton 2014, 
Galal 2009). From these various phenotypes have arisen much scientific and legal debate. 
Within the forensic community there are two distinctive ideologies of the classification of 
the Cannabis genus, monotypic vs. polytypic (Hillig 2004, Hillig 2005). In 1753 Carrolous 
Linneaus purported the Cannabis species was composed of only one species (monotypic) 
Cannabis sativa L (Linneaus). Jean-Baptiste Lamarck published his findings in 1785 stating there 
were different species (polytypic) cannabis sativa and cannabis indica. Where sativa was 
composed of mainly the fiber type and indica was predominantly the drug type. In 1974 Schultes 
took the classification one step further and recognized three phenotypes and gave them each their 
own name. Cannabis indica classified as having high THC content and thus being the drug type, 
cannabis ruderalis as being the fiber type, and cannabis sativa being the intermediate  (Shultes 




there is only one species cannabis sativa l. These distinctions become even more convoluted as 
the strains have been selectively interbred to produce various products with very different 
purposes. 
TAXONOMY 
Cannabis belongs to the Cannabaceae family along with another widely known plant 
Humulus (Hops). Cannabis is an annual plant where male and female flowers are found on 
separate plants (dioecious). Although in rare circumstances, monoecious examples of cannabis 
have been observed. Staminate (male) plants are in general taller and less robust than their 
pistillate (female) counterparts (UNODC 2009). The method of cultivation, the environment, and 
genetic factors all effect the height and branching of the plant. Most cannabis plants are erect and 
can grow anywhere from 1-3 meters high with their stem diameter ranging from 0.2-0.6 m 
(Figure 1) (UNODC 2009). The taproots are laterally branched 0.3-2.5 m deep and can have 
horizontal growth as much as 0.8m wide (Upton 2014). Cannabis leaves are palmately compound 
with odd numbered leaflets ranging from 3-11 leaflets. Leaflets have serrated edges with a 
lanceolate shape. The middle or apex leaflet is typically the longest (Potter 2004, 2009, 2014). 
The cannabis leaf has many trichomes or hair-like structures. On the upper portion of the leaf, 
there are cystolithic “bear claw” shaped non-glandular trichomes (Figure 2). A whitish 
appearance can be observed at the base of the cystolith. These are calcium carbonate crystals 
(Figure 3). On the lower surface of the cannabis leaf, there are profuse and slender covering 
trichomes (Figure 4). Many glandular trichomes can also be observed on the lower surface where 
the resin or cannabinoids are secreted (Figure 5). Seeds (achene) from the hops plant and 
cannabis plant can be confused by a novice. However, the reticulate or tortoise shell pattern 





Cannabis can be selectively bred to produce desirable traits. The drug type often has high 
levels of THC and low levels of CBD. This is attained by removing the staminate plants and only 
growing female cannabis. This growing and cultivation technique is called sinsemilla or “no 
seed”. The female plants will produce high levels of sticky resin, increasing the chances of 
encountering pollen and producing seeds. Without the male plants, the pistillate high THC 
cannabis flowers or “buds” can then be harvested. The main type of cultivation is still outdoors. 
Sensemilla is achieved by removing or cutting down the male plants as soon as they can be 
identified. Indoor cultivation can induce sensemilla by propagating cuttings of the female plants 
(Cervantes 2006, Mills 2011). The cuttings then grow and are identical to the female mother 
plant. This technique is sometimes referred to as cloning (Bosca 1997). All of the desired female 
plants are grown and not the male plants. This is the preferred indoor propagating method as it 
ensures efficiency.  
 Harvest time can vary depending on the type and desired cannabinoid. The primary 
cannabinoid the cannabis plant makes is called delta 9-tetrahydrocanabinolic acid or THCA. The 
THCA is a very unstable compound and is naturally decarboxylated to THC when introduced to 
air, light, and heat (Harvey 1976, McPartland 1996, 2000, 2001, 2008, Upton 2014, Jones 2010). 
THC is at its peak potency when three-fourths of the stigmas have turned brown (Figure 7). The 
resin will also be clear at this time (Figure 8). Once the resin on the bud turns to an orange or 
brown, it is over ripe and the THC content has degraded into CBN (Figure 9A, 9B). Peak 
clandestine harvest in Kansas is during the month of September. Typically cannabis plants are 
sold as dried and mature female buds that have been manicured with their seeds and stems 
removed (Figure 10). Cannabis can be found growing wild throughout the state of Kansas. This is 






Under the federal regulations in the United States, the Controlled Substances Act (CSA) 
regulates compounds that have a psychoactive effect on the CNS and have the potential for abuse. 
The Controlled Substances Act regulates the authority to control schedules, manufacturers, 
distributors, dispensers, offenses, penalties, enforcement provisions, import, and export of each 
controlled substance. Each compound listed under the CSA are provided a classification that is 
called a schedule. In total there are five schedules with Schedule I substances having the highest 
probability of becoming addictive and Schedule V being the least likely to be used for abusive 
purposes.  
Schedule I is any compound that has a high probability for abuse, has no current medical 
use within the United States (U.S.), and there is a lack of safety reported even under medical 
supervision. Schedule II is any compound that has a high probability of abuse, has current 
medical applications with severe restrictions within the U.S., and may cause severe dependency. 
Schedule III has some possibility of abuse although to a lesser degree than Schedule I and II, has 
current medical applications within the U.S., and may cause moderate to low dependency. 
Schedule IV has a lower probability of abuse when compared to Schedules I, II, and III, has 
current medical applications within the U.S., and cause very limited dependence possibilities 
(DEA 2011a, Mead 2017). 
Cannabis is still considered a Schedule I controlled substance under the federal CSA. 
Examples of drugs that fall into the same category are: methamphetamine, phencyclidine (PCP), 
and heroin. Since cannabis is a Schedule I drug The Drug Enforcement Agency (DEA) has strict 
control over the possession and transportation (DEA 2011b). The DEA stipulates cannabis must 
travel from one DEA licensed facility to another DEA licensed facility.   As of 2017, the only 
federally recognized facility that is able to cultivate cannabis for medical and research purposes is 




applications to manufacture marijuana for research purposes in August of 2016. The program 
registrants would operate under the CSA. To date, the DEA has not accepted nor rejected any 
candidate. Likewise, the Agricultural Act of 2014 Section 7606 “Farm Bill” has made an 
allowance for the term “industrial hemp”. Industrial hemp is defined by the National Institute of 
Food and Agriculture (NIFA) section of the United States Department of Agriculture (USDA) as 
“the plant cannabis sativa L. and any part or derivative of such plant, including seeds of such 
plant, whether growing or not, that is used exclusively for industrial purposes (fiber and seed) 
with a tetrahydrocannabinols concentration of not more than 0.3 percent on a dry weight basis”. 
The Farm Bill gives federal direction as how to legally participate in hemp research, in states 
where such activity is legal (USDA 2016). Additionally, each (NIFA) program applicant must be 
an institution of higher education or state department of agriculture (or designee) and grow 
industrial hemp under the umbrella of a state agriculture pilot program. Each state where 
industrial hemp is legal interprets the Farm Bill differently and who the state’s Department of 
Agriculture may authorize to participate in the program.  
Health care providers in all 50 states can prescribe a drug called Dronabinol (Bolognini 
2010). It is a synthetic and FDA approved form of THC. It is specifically produced in sesame oil 
and encapsulated in a soft gelatin capsule. Dronabinol, also known as Marinol is a Schedule III 
controlled substance that is used to treat nausea and vomiting caused by cancer treatments or 
weight loss in AIDS patients (Neff 2002, Nelson 1994). 
State laws on CBD vary widely as currently seventeen states allow products high in CBD 
and low in THC (Mead 2017). Although many CBD products are available on the internet and 
dispensaries however they are neither approved nor regulated by the FDA. Quality control 
measures on CBD are at best inconsistent and sometimes nonexistent. New and recent clinical 
trials have begun to focus on the potential for use of CBD to treat childhood seizure disorders 




As of September 2017, twenty-nine states and the District of Columbia currently have 
vague laws legalizing marijuana in some form (Figure 12).  Seven states in addition to the District 
of Columbia have adopted laws legalizing marijuana for recreational use (NCSL 2017).  
KANSAS STATUS  
Kanas state law defines marijuana as, “meaning all parts of all varieties of the plant 
Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant 
and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds 
or resin. "Marijuana" does not include the mature stalks of the plant, fiber produced from the 
stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, 
derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, 
oil or cake or the sterilized seed of the plant which is incapable of germination.” Similar to 
federal regulations, cannabis and THC are considered a Schedule I controlled substance under the 
CSA.  Unlike federal regulations, there are no current provisions to grow cannabis for research, 
medical considerations, or for industrial hemp. All types of cannabis within the state are treated 
the same according to Kansas law (Kansas Legislature 2014). 
 
PHARMACOLOGY 
 Merriam Webster defines Pharmacology as the science of drugs including their origin, 
composition, pharmacokinetics, therapeutic use, and toxicology. As stated, cannabis is considered 
a Schedule I drug: however there is a lot of research that still needs to be conducted as to its 
pharmacology (Dewey1986). The cannabis plant has over 400 compounds and out of those there 
are over 60 cannabinoids (Figure 13) (Mechoulam 1990, 2002). To date THC and CBD are the two 
most widely studied cannabinoids.  THC is readily absorbed through the lungs via inhalation 




ingested the body converts THC into 11-hydroxy THC which is then further degraded into its 
non-psychoactive form 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (Sharma 2012). THC is 
lipophilic and gets deposited in the adipose, lung, liver, and spleen tissues.  For the infrequent 
user the half-life for THC is 1.3 days and for frequent users is anywhere from 5-13 days with the 
longest being in the adipose tissues (Sharma 2012). 
 There are also psychological and physiological symptoms reported with cannabis use. 
Physiological effects have been reported as dry mouth, increased appetite, vasodilation, decreased 
respiratory rate, rapid changes in heart rate, and redness of the conjunctiva. Abuse of cannabis is 
also known to damage the lungs and affect neonatal child development (Huestis 2002). 
Psychological effects have been described as a feeling of euphoria and relaxation, altered time 
perception, lack of concentration, impaired learning and memory, mood changes, feeling of panic 
and paranoia, and impaired motor coordination (Izo 2002, EMCDDA 2006, EMCDDA 2008, 
EMCDDA 2012). 
 THC acts as a dopamine agonist by stimulating the electrical brain reward system 
(Huestis 2002). As common with most drugs of abuse research has shown that THC induces 
stimulation of the brain rewards systems that are common with opioids, cocaine, and alcohol. A 
dependence of cannabis are characterized by preoccupation with its use, relapse or recurrent use, 
and impaired control of their use (Sharma 2012). Cessation syptoms from frequent users are 
described as irritability, anxiety, disrupted sleep, and cravings.   

















GAS CHROMATOGRAPHY MASS SPECTROMETRY 
Gas chromatography mass spectrometry or (GCMS) is used in virtually every forensic 
laboratory. It is also considered the “workhorse” of detecting the presence of controlled 
substances. GCMS is also considered the “gold standard” for drug detection. It is desirable to be 
able to utilize the GCMS technology because of its robustness and availability with in the 
forensic laboratory.   
The retention time of the obtained peak and the mass spectrum can provide an absolute 
recognition of the tested compound. The GCMS combines two instruments, the gas 
chromatograph and the mass spectrometer. The gas chromatograph uses a capillary column and a 
variety of stationary phases. A carrier gas is used as the mobile phase. When a compound or 
analyte is injected onto the column, it will interact with the column based on certain properties 
such as polarity, shape, molecular weight, and viscosity. How long the analyte stays in the 
column is referred to as its retention time. In theory each analyte will have a specific and unique 
retention time. Thus it has the ability to separate a mixture of compounds. Once the analyte 
moves through the column it then enters the mass spectrometer. The mass spectrometer fragments 
each anaylte into particular fragments into a unique pattern which can be used for the 
identification of a compound.  The fragments or puzzle pieces break apart in a very particular and 
predictable way. The fragments are then sent to a detector and data is collected. Based on the 




of marijuana as the mass spectrometer is considered a Category A test and the gas chromatograph 
is a Category B test. Both tests together produce a high level of selectivity and specificity.   
GC technology is always evolving. Selected ion monitoring (SIM) increases sensitivity 
for target analytes through selective detection of ions most indicative of the compounds of 
interest. GCMS selected ion monitoring methods are useful and widely applied although they are 
somewhat complicated to develop depending on the number of ions used. SIM is most often used 
for target compound analysis. Recent changes to the GCMS methods allow for SIM and Scan 
modes to be carried out simultaneously. SIM methods can lock in the retention times of interest. 
Scan mode can verify each analyte by matching the corresponding retention times from the 
chromatogram and their spectrum. Running SCAN mode in addition to SIM mode also ensures 
there are no analytes within a mixture that elute at different times than the compounds of interest. 
Hence the SCAN mode mass spectral information provides additional confirmation to detecting a 
compound. This can allow for presumptive and confirmatory runs to also be conducted 
simultaneously.  
LIQUID CHROMATOGRAPHY MASS SPECTROMETRY 
 Liquid chromatography mass spectrometry or (LCMS) is similar to GCMS. It is a 
technique used to identify substances. LCMS uses a liquid solvent for the mobile phase similar to 
how the GCMS uses a gas. A LCMS also has high sensitivity and selectivity. One difference 
between LCMS and GCMS is that in LCMS a substance does not have to become volatile in 
order for it to be put onto the column. Heat labile analytes can be ran through the column without 
being degraded before they go into the mass spectrometer. Sample types can range from low 
molecular weight compounds to complex protein matrices. This makes the LCMS suitable for 
ionic, polar, and thermally unstable non-volatile compounds. This also eliminates the need for 
derivitization that is sometimes needed in GCMS. Another advantage to LCMS is shorter run 




20 minutes while the LCMS is  5-7 minutes. A couple of drawbacks to using the LCMS is they 
are generally less robust than the GCMS, require more maintenance, and are more costly.  
 Using both a UV detector and a mass selective detector increases sensitivity and 
selectivity. A diode array detector acquires data for a range of wavelengths producing spectra. 
There are analytes or compounds that absorb at a similar wavelength making it difficult for the 
UV detector to distinguish between. It is also possible to have analytes or impurities with the 
same mass. However, it is rare for similar analytes to have the same UV-Vis spectra as well as the 
same mass spectra. The data for a range of wavelengths can be collected simultaneously. Specific 
wavelengths can be selected post run and chosen to analyze mass spectrum to determine 















METHODS AND MATERIALS 
 
 
GCMS- Gas chromatographic analyses was performed on two different instruments and 
were comprised of the following components: Agilent GC 7820A, Agilent 5977B MSD single 
quadrupole detector, GC column Phenomenex, Zebron Capillary Column ZB-5MSi 12m x 200µm 
ID, 0.33 µm film thickness, Agilent 7890B GC, 5977A MSD single quadrupole detector, GC 
column Agilent, Capillary Column J&W HP-5  30m x 250µm ID, 0.1 µm film thickness. The 
injector port temperature was set at 280oC with a 5.2 mm split/splitless deactivated glass wool inlet 
liner.  A 10:1 injection ratio was used and helium was the carrier gas. The carrier gas flow was 
maintained at 1.5005 mL/min. The initial oven temperature was set at 65oC and held for 0.2 min, 
then ramped 25 oC/min to 335 oC. The transfer line was set at 285 oC. The mass spectrometer 
operated in selected ion monitoring (SIM)/Scan acquisition mode. For the quantitation two ions 
were selected. The ion 299 was selected as it is the base peak for THC. The second ion selected 
was 57 as it was the base peak for tetradecane. When processing data using tribenzylamine, the ion 
91 was used as it is the base peak. Mass Hunter Quant Analysis software was used process data.  
HPLC- Liquid chromatographic analyses performed were comprised of the following 
components: Waters Acquity H-class UPLC Quaternary Pump, Waters Acquity H-class Sample 
Manager – FTN (flow-through needle), Waters Acquity PDA (photodiode array detector), Waters 
Acquity QDa (electrospray ionization single quadrupole mass spectrometer), Waters Acquity 
UPLC CSH C18 1.7 µm particle, 2.1 mm x 100 mm column. The run time was 6.50 minutes with 




resolution was 3.6nm with a range of 210-350nm. Mobile phase solvents were (A) water, (B) 
acetonitrile, (C) 125mM Formic Acid, and (D) 125mM Ammonium Hydroxide with gradient 
concentrations of 0.6mL/min. The separation was performed with the following gradients: 0-3.75 
min, (20%-0% A, 70%-90% B, 10% D), 3.75-5.00 min (90%-70% B, 10% D), 5.01- 6.49 min 
(20%-0% A, 70%-90% B, 10% D). The injection volume was 1µL and detection was at 214 nm. 
MassLynx and OpenLynx software was used to process the data. Electronspray interface was 
operated in positive mode. 
REAGENTS AND STANDARDS 
ACS grade ammonium hydroxide was purchased from VWR International, Radnor, PA. 
OPTIMA-grade acetoniltrile and OPTIMA grade formic acid, tetradecane 98% pure, Pharmco-
Aaper ethyl alcohol 200 proof was purchased from Fisher Scientific, Pittsburg,PA. Deonized 
water was purified by an in-house 18mΩ gradient filtration system. Standards were purchased 
from Cayman Chemical, Ann Arbor, MI. All standards were certified reference materials and 
were in solution at 1.0 mg/mL. Fresh ampules were used to ensure consistent and accurate data.  
GCMS DECARBOXYLATION 
 All vegetation was analyzed via the microscope. Vegetation samples had to have the 
characteristic cystolithic trichomes or hairs and the covering hairs to be considered cannabis 
(Figure 4). Then vegetation samples were examined for approximate cannabinoid content. If large 
amounts of resin was observed (Figure 9A, 9B), it was notated and dilutions were anticipated.  
Approximately five grams of vegetation were ground for ten seconds, then ten one second pulses. 
The ground powder was dried at 35-40oC for one hour. From the dried and ground samples, one 
hundred milligrams were weighed out on an analytical balance.  Ten milliliters of ethanol spiked 
with tributylamine (0.153 mg/mL) were added to the dried vegetation and vortexed for 5 seconds. 




milliliter syringe. This was followed by pipetting 500 µl of the extract into a GC vial. It was then 
diluted with 1 mL of ethanol spiked with tributylamine to a total volume of 1.5mL.  
 A THCA curve was run along with ten evidence sample extracts (Table THCA Curve). 
Then a THC calibration curve was run along with ten evidence sample extracts (Table THC 
Curve).  Blanks were run between each extract sample to monitor carryover (Figure TBA RT, 
Figure TBA Spectrum). Drug standards were made from 1.0 mg/mL certified reference materials 
at concentrations ranging from 0.16 mg/mL -0.54mg/ml. Stock solutions of individual THC 
standards were prepared in 25 mL Class A volumetric flasks. Stock solutions of individual THCA 
standards were prepared by pipetting various concentrations into 2 mL GC vials. Tributylamine 
was used at the internal standard at a concentration of 0.153 mg/mL. The filtered extracts and 
standards were capped after runs and stored at 20 oC. After approximately 10 days the TBA, 
THCA, and THC started to degrade and another internal standard was needed. 
GCMS QUANT 100 SAMPLES 
One hundred seized cannabis evidence samples were examined. All vegetation was 
analyzed via the microscope. Vegetation samples had to have the characteristic cystolithic 
trichomes and the covering trichomes to be considered cannabis (Figure 4). Then vegetation 
samples were examined for approximate cannabinoid content. If large amounts of resin was 
observed (Figure 9A, 9B), it was notated and dilutions were anticipated.  Approximately five 
grams of vegetation were ground for ten seconds, then ten one second pulses. For treatment one 
the ground powder was dried at 35-40oC overnight. For treatment two and three they were dried 
35-40oC for 1 hour. From the dried and ground samples, three hundred milligrams were weighed 
out on an analytical balance. Five milliliters of  100% ethanol spiked with 0.153mg/mL 
tetradecane were added to the dried vegetation and vortexed for five seconds. Treatment two was 
filtered with a 0.45 µl filter and a 20 milliliter syringe and treatment 3 was filtered with a cotton 




standards were made from 1.0 mg/mL certified reference materials at concentrations ranging 
from 0.09 mg/mL -0.53mg/mL. Tetradecane was used at the internal standard and was at a 
concentration of 0.153 mg/mL. The filtered extracts and standards were capped after runs and 
stored at 20 oC. A retention time of THC was determined to be 9.4 min ± 1%.  Septum and liner 
were changed after every 100 runs. A series of four solvents (methanol, acetone, chloroform, and 
ethanol) were run between every five samples to keep the internal standard response to the 
detector more stable.  
LCMS CANNABINOID QUALITATIVE ANALYSIS 
A series of CBN, CBD, THC, and THCA were added to a GC vial and qualitatively run 
on the LCMS (Figure 20). It is important for the LCMS to be able to differentiate between the 
commonly occurring cannabinoids with adequate resolution. Certified reference materials were 
used from an accredited ISO/IEC 17025 and ISO Guide 34:2009 supplier with certificate of 
analysis provided. The cannabinoid test mix was made from 1.0 mg/mL certified reference 
materials. The standards were capped after runs and stored at 4 oC. Blanks were ran between each 
evidence extract sample to monitor carryover. Each cannabinoid was confirmed by referencing 
their mass spectrum and, retention times, and their parent ion fragment. 
LCMS QUANTITATIVE ANALYSIS 
A series of 15 evidence samples were examined. Then vegetation samples were examined 
for approximate cannabinoid content. If large amounts of resin was observed, it was notated and 
dilutions were anticipated.  Approximately five grams of vegetation were dried for 3 hours at 35-
40oC. Vegetation was dried to maintain minimal levels of water within the samples. The 
vegetation was then ground for ten seconds, then ten one second pulses. Two hundred milligrams 
were weighed out on an analytical balance and placed into a glass shell vial. Twenty-five 
milliliters of ethanol were added to the dried vegetation and sonicated for fifteen minutes with 




µl filter and a 20 milliliter syringe. From the filtered extract, 100 µl were added to a two mL GC 
vial and placed in an oven at 150oC for ten minutes to ensure complete decarboxylation of THC. 
The dried extract was reconstituted in 1mL of ethanol. Blanks were run between each evidence 















RESULTS AND DISCUSSION 
 
 
In the decarboxylation trial, an inlet temperature of 280oC was tested to monitor the 
decarboxylation of THCA. A THC curve and a THCA curve were run in the same batch along 
with the 15 evidence samples. Then each curve was used to quantitate the evidence samples. The 
inlet temperature was set at 280 oC based on the validated method of (UNODC 2009). The 
calibration curves were both linear and concentrations of THC were calculated. The 
concentrations of the evidence samples were not the same when the THCA curve was used as 
when the THC curve. When the THC curve was used to quantify samples, all of the THCA 
samples were consistently low (Table III). When the THCA curve was used to quantify samples, 
all of the THC samples were consistently high (Table II). This was due to a calculation error. The 
conversion factor of 0.877 should have been used in order to account for the different molar mass 
of THCA after decarboxylation when mixing the THCA standards. When the 0.877 calculation 
conversion to THCA is applied, the THC concentrations appear to be fully decarboxylated in the 
inlet. 
 The THC curve was linear with a correlation coefficient (r2) of 0.998 (Figure 14B). The 
THCA curve was linear with a correlation coefficient (r2) of 0.989 (Figure 14A). All of the 
quantitations (mg/mL) were calculated in MassHunter software and the total percent THC was 
calculated by the following: THC%= (mg/mL cannabinoid in sample X volume of sample (mL) 
X dilution factor) / (mass of sample X 106) *100%. Each blank ran before the evidence sample 




confirmed in the chromatograms as the peaks were fully resolved and no co-elution was 
observed. Each analyte within the sample extracts were identified by their retention times as well 
as their mass spectrum. The method was derived from the validated general drug screen that is 
typically used in casework so selectivity had already been determined. After approximately 10 
days, interactions with the internal standard and THC were observed as both revealed degradation 
as well as new compounds formed in the chromatograms. This required the development of a new 
internal standard and tetradecane was chosen because of its non-polarity. 
 In the 100 evidence sample trial, all evidence samples were run on the Agilent GC 7820 
and various samples were run on the Agilent GC 7890 (Table IV. A., B., C., D.,). The samples 
were also prepared by more than one forensic scientist. The average percent of THC in the 100 
evidence samples was 10.29%, the maximum was 23.25%, and the minimum was 0.29%. The 
quality control samples as well as the standards routinely did not meet the +/- 20% accuracy 
requirement (Figure 19). A linear calibration curve was produced by plotting the response of 
STD/ISTD (y) against concentration (x). The standard curves were also not consistent. Standard 
curves had to be re-run as well as fresh batches had to be made while still failing to meet +/- 20% 
accuracy requirement. The relative standard deviation for all of the samples ranged from 0.00-
3.13%, while the relative standard deviation for the internal standard ranged from ranged from 
6.10-25.77%. All of the quantitations (mg/mL) were calculated in MassHunter software and the 
total percent THC was calculated by the following: THC%= (mg/mL cannabinoid in sample X 
volume of sample (mL) X dilution factor) / (mass of sample X 106) *100%. The limit of detection 
(LOD) and limit of quantitation (LOQ) was calculated using the standard error (produced in 
excel) of the y intercept (Table IX). The LOD was 0.09 mg/mL and the LOQ was 0.28 mg/mL. 
These numbers correspond with a 0.1% and 0.4% THC respectively on a dry weight basis. 
The qualitative cannabinoid study evaluated the selectivity by looking at the commonly 




interfering peaks were detected at the target retention times. Then the cannabinoid mix was run 
and the chromatographic peaks were monitored (Figure 20). Low and high cone voltage spectra 
were produced at 1.54 minutes, 1.96 minutes, and 2.32 minutes. The spectra at 1.54 minutes was 
indicative of CBD, the spectra at 1.96 minutes was indicative of CBN, and the spectra at 2.32 
minutes was indicative of THC. It also appears THCA co-elutes at 2.28 minutes however since 
the method allows for decarboxylation in the oven before samples were placed on the instrument 
was not an issue. 
For the quantitative THC study, a five point calibration curve was performed on each day 
for a total of 3 non-consecutive days. The five prepared standards were analyzed with every batch 
and used to determine the linearity of the instrument response. The calibration standard solutions 
were made with calibrated mechanical pipettes. A serial dilution of drug standards were made 
from 1.0 mg/mL certified reference materials at concentrations ranging from 0.00097 mg/mL - 
0.5 mg/ml. A series of 15 evidence samples were ran along with the curves each day for a total of 
3 non-consecutive days (Table VI. A., B., VII A., B., VIII. A., B.). As previously stated, the 
samples were run on non-consecutive days as well as by more than one forensic scientist. All 
seized evidence samples were within the calibration range.  
Acceptance criteria stated the linear correlation coefficient could not be below 0.99 and 
the accuracy had to be within ± 20% of the THC target. Peak shape was excellent with no signs of 
chromatographic abnormalities. The r2 for all of the batches were greater than the 0.99 for the 
THC target compound which meets the acceptance criteria of ≥ 0.99 and also met the ± 20% of 
the THC target acceptance criteria.  For repeatability the percent relative standard deviation 
(RSD) of the peak area from the 15 samples analyzed was calculated. The batches ran showed an 
RSD ≤ 0.0798 %. The low RSD demonstrates that the method was precise in terms of needle 
injections and response to the detector during each days run. The intermediate precision showed 




calculated using the standard error (produced in excel) of the y intercept (Table X). The LOD was 
0.000002 mg/mL and the LOQ was 0.000006 mg/mL. These numbers correspond with a 0.0002% 
and 0.00085% THC respectively on a dry weight basis. 
Focus on cannabis has increased as states legalize varying degrees of usage. Whether it 
be extracts, edibles, or new and improved strains, the application and testing vary widely. Testing 
methods can be simple and efficient or long and laborious. In the quantitative methods created, 
procedures were long, labor intensive, as well as drastically increasing laboratory supplies 
needed.  
Ideally a robust GCMS method was hoped to be developed as they are the workhorse of 
most drug chemistry laboratories. The difficulty with the internal standard interactions with the 
THC standard was unanticipated. Tribenzylamine was first chosen as it had been successfully 
been used to quantitate THC. The stability of THC was also overestimated. In the UNDOC 2009 
reference, TBA was used along with CBN instead of THC. CBN is inherently more stable than 
THC. Since we never see degradation of our THC standards in our routine qualitative analysis, 
the stability of THC was not thought to be an issue. This was not the case. During the study, 
keeping standards and evidence samples at refrigerated or freezing temperatures was important 
although not always practical. In regular GCMS casework a forensic scientist may start a 
sequence that lasts several days. The autosamplers were not temperature or light controlled and 
visible degradation started even at room temperature. This also caused a lot of waste as each 
standard was prepared in a 25 mL Class A volumetric flask. 
At one point in the study sample extracts were kept in the refrigerator as space in the 
freezers were very limited. This particular refrigerator had a glass door and would catch the 
Eastern morning sun. In just a few short days, the sample extracts went from a chlorophyll green 




unstable in the presence of light. This further supports the information presented on cultivation 
and the conversion to CBN depicted in Figures 9A. and 9B. If the issue of temperature and light 
control can be addressed, using TBA as an internal standard may be revisited. 
At the beginning of the study, it became apparent that the grinders purchased were not 
adequate (Figure 27). There would be some loss of resin in the grinding step and recovery would 
not be 100%. Grinding before drying the cannabis and grinding after drying the cannabis in the 
oven was observed. There was considerably more resin left in the grinders than predicted as most 
of the evidence samples were either several years old or came from other states and were from 
dried retail product. The size of the ground product was also questioned. The idea of using 
cryogenic grinders or liquid nitrogen with mortar and pestle were explored as they would 
additionally address the size of the ground product and homogeneity. More research needs to be 
conducted as to the best method for recovery as the grinders we have would be deemed 
unacceptable in casework.  
In the decarboxylation trial, complete decarboxylation of THCA in the GCMS inlet was 
desired as derivitization would make the method more problematic. In order to work efficiently 
and effectively, it is better to calculate and quantitate the neutral form of THC instead of the 
neutral and acidic forms. A prior heating step was also tested however it was deemed unnecessary 
because the conversion of THCA to THC was complete upon injection into the GCMS. The 
concept of total THC content was applied and any deviation from this would result in increased 
labor and supplies. Another thing to note is the r2 for the THCA curve was lower than the THC 
curve. This was most likely due to the amount of standard prepared. The cost for 1mg/mL of 
THC is significantly lower than the same quantity of THCA. As such, the THC standards were 
prepared in 25 mL Class A volumetric flasks while the THCA standards were 1mL total. 




Initially we couldn’t determine why when using the THCA curve, all of the THC 
standards were quantified in unusually low concentrations and the opposite was true when using 
the THC curve. This was eventually solved as we did not use the 0.877 conversion factor in order 
to account for the different molar mass of THCA after decarboxylation when mixing the THCA 
standards. It was assumed the starting concentration was 1 mg/mL stock solution of THCA to 
make the standards. Once injected into the GCMS, the acid portion of the THCA was cleaved and 
no longer were working with a stock solution of 1 mg/mL. Once the 0.877 conversion factor was 
used, the concentrations of the evidence samples and standards were more consistent. 
The GCMS instruments available to the drug chemistry section only had one quadrupole 
rather than a triple quadrupole. This severely limited the ability to quantitate at low 
concentrations. While the samples were ran in SIM/Scan mode, the detector was still not 
sufficiently sensitive to detect concentrations that are indicative of hemp. It was difficult to 
maximize the instrument so the detector would detect the 0.09 mg/mL standards (0.1% THC). 
With the difficulty of the instrument, it is not surprising that most of the QC samples did not meet 
the acceptance criteria of ± 20%. 
The internal standard tetradecane was chosen as it was a non-polar compound and 
thought to have less interactions with THC than the TBA internal standard. Tetradecane did show 
to be more stable than TBA however it had challenges as well. The internal standard response to 
the detector would drastically decrease with no apparent reason. Septum and liner were replaced 
after every 100 runs. This irregular detector response was irrespective as to when the septum and 
liner was changed. In order to alleviate the irregularity, a series of four different solvents were run 
between every 5 samples. This drastically increased batch sequences and runtimes. It appeared 
cleaning the source once a week was also necessary. This is less than desirable as cleaning the 
source is time intensive and greatly decreases the number of samples that can be ran during a 




Since the data from the GCMS was unreliable, the possibility of developing a quantitative 
method on the LC-UV-MS was explored. Since resolution and reproducibility of the LCMS is 
much greater, only external standards were used. The cannabinoid test mix was run to determine 
selectivity. All cannabinoids were fully resolved except THCA. THCA co-eluted with THC based 
on the information provided by the total ion chromatogram. This was not considered an issue as 
the method developed had incorporated a decarboxylation step that would fully convert THCA to 
THC prior to injecting the extracts onto the column. Further controlled substances still need to be 
researched in order to be validated for casework. CBN, CBD, THC, and THCA was used based 
off of experience in casework as to the most common compounds found within a cannabis 
sample. 
The wavelength 214 was initially used to quantify the evidence samples as it is a 
common wavelength for controlled substances to absorb. The method was developed based off of 
a validated methamphetamine quantitation method already used in casework at our laboratory. 
Through testing, THC and the other major cannabinoids frequently encountered in casework did 
in fact have an absorbance at 214nm. With the confirmation of the absorbance peak at 214nm, 
THC was deemed acceptable to quantitate THC samples. This allows uniformity in placing 
various controlled substances under one method. The mass spectrometer was used to detect ions 
within the same analytical run so a presumptive and confirmatory test can be conducted 
simultaneously. The LCMS method demonstrated a wide dynamic range as well as excellent 
reproducibility. The LCMS itself has the capability to yield high throughput and with a runtime of 
6.5 minutes could help reduce backlog in casework. Although to achieve this, changes and 
advances to the method need to be investigated as well as slightly different columns. 
 Overall this project demonstrated scientifically relevant data in regards to forensic 
applications. The goal of the project of determining which method would best quantitate THC 




suitable for the high sample volume seen in forensic casework as their average runtimes were 
over 30 minutes. The LC-UV-MS is more than capable of quantitating a large range of THC 
concentrations observed in routine cannabis samples. Despite the fact that the LCMS method was 
suitable for casework more additional research should be concentrated on finding more cost 
effective solvents and supplies since ethanol is expensive and evaporates very quickly. Further 
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TABLE 1. SWGDRUG 
 

























Sample Name  Final Conc Exp Conc Accuracy
THC Std 1 - 0.167 mg/mL 0.2172
THC Std 2 - 0.25 mg/mL 0.3009
THC Std 3 - 0.35 mg/mL 0.4010
THC Std 4 - 0.53 mg/mL 0.6533
THC-A Std 1 - .016 mg/mL 0.1776 0.1600 111.01
THC-A Std 2 - 0.24 mg/mL 0.2252 0.2400 93.83
THC-A Std 3 - 0.34 mg/mL 0.3349 0.3500 95.68











THC-A Std 3 - 0.34 mg/mL 0.3334 0.3500 95.24




TABLE 3. THC Curve 
 
  
Sample Name  Final Conc Exp Conc Accuracy
THC Std 1 - 0.167 mg/mL 0.1738 0.167 104.0966
THC Std 2 - 0.25 mg/mL 0.2454 0.25 98.17835
THC Std 3 - 0.35 mg/mL 0.3310 0.35 94.57224
THC Std 4 - 0.53 mg/mL 0.5467 0.53 103.1528
THC-A Std 1 - .016 mg/mL 0.1400
THC-A Std 2 - 0.24 mg/mL 0.1807
THC-A Std 3 - 0.34 mg/mL 0.2745











THC-A Std 3 - 0.34 mg/mL 0.2732


















9 7.42% 11.01% 9.03%
1.23% 1.31% 0.09% STD DEV
10 7.17% 8.17% 8.32%






16 8.11% 7.59% 7.68%
0.37% 0.14% 0.08% STD DEV
17 7.99% 8.74% 6.32%
0.22% 0.75% 0.96% STD DEV
18 9.50% 8.34% 7.20%
0.81% 0.00% 0.81% STD DEV
19 8.95% 9.42% 10.83%
0.55% 0.22% 0.78% STD DEV
20 8.11% 14.25% 14.81%
3.03% 1.32% 1.71% STD DEV
21 7.48% 8.14% 8.50%
0.40% 0.07% 0.33% STD DEV
22 12.42% 9.35% 11.91%
0.84% 1.33% 0.48% STD DEV
23 12.54% 10.03% 11.04%
0.95% 0.83% 0.12% STD DEV
24 7.94% 9.44% 9.87%











25 11.39% 11.81% 11.53%
0.13% 0.16% 0.03% STD DEV
26 13.27% 12.06% 17.38%
0.68% 1.54% 2.22% STD DEV
27 10.36% 10.99% 10.40%
0.16% 0.29% 0.13% STD DEV
28 9.95% 8.93% 9.67%
0.31% 0.41% 0.11% STD DEV
29 9.55% 13.04% 9.57%
0.83% 1.64% 0.81% STD DEV
30 17.60% 15.74% 14.35%
1.21% 0.11% 1.09% STD DEV
31 14.36% 12.67% 10.99%
1.19% 0.00% 1.19% STD DEV
32 9.80% 13.55% 10.47%
1.04% 1.61% 0.57% STD DEV
33 10.85% 13.40% 11.25%
0.69% 1.11% 0.41% STD DEV
34 9.87% 10.43% 10.92%
0.38% 0.02% 0.36% STD DEV
35 9.04% 8.21% 9.15%
0.17% 0.42% 0.25% STD DEV
36 8.40% 9.84% 9.34%
0.56% 0.46% 0.10% STD DEV
37 14.11% 14.22% 15.25%
0.29% 0.22% 0.51% STD DEV
38 16.82% 15.16% 13.50%
1.17% 0.00% 1.17% STD DEV
39 14.52% 13.83% 17.16%
0.46% 0.95% 1.41% STD DEV
40 13.96% 17.16% 19.30%




TABLE 4C. 1-100 
  
41 9.45% 9.34% 8.51%
0.25% 0.17% 0.42% STD DEV
42 9.57% 8.57% 10.31%
0.06% 0.65% 0.58% STD DEV
43 9.58% 9.99% 10.08%
0.22% 0.08% 0.14% STD DEV
44 8.75% 14.99% 11.39%
2.09% 2.32% 0.23% STD DEV
45 9.08% 9.21% 9.27%
0.08% 0.02% 0.06% STD DEV
46 10.69% 11.43% 10.60%
0.16% 0.37% 0.22% STD DEV
47 17.90% 15.71% 16.51%
0.84% 0.70% 0.14% STD DEV
48 14.16% 12.21% 11.83%
1.01% 0.37% 0.64% STD DEV
49 20.56% 11.70%
3.13% 3.13% STD DEV
50 14.35% 15.02% 11.79%
0.45% 0.92% 1.36% STD DEV
51 19.62%
52 21.12% 16.39% 16.78%
2.14% 1.21% 0.93% STD DEV
53 17.13% 17.90% 15.69%
0.16% 0.70% 0.86% STD DEV
54 15.58% 15.13% 13.65%
0.56% 0.24% 0.80% STD DEV
55 8.38% 8.31% 7.66%
0.19% 0.14% 0.32% STD DEV
56 8.71% 8.69% 8.39%
0.08% 0.07% 0.15% STD DEV
57 8.87% 8.48% 9.81%
0.13% 0.41% 0.53% STD DEV
58 14.01%
59 13.89% 16.22% 14.48%
0.69% 0.96% 0.27% STD DEV
60 16.59% 16.43%

















































TABLE 5. GCMS DATA 
 
  
Sample Name  Final Conc Exp Conc Accuracy
THC Std 1 - 0.09 mg/mL 0.0874 0.09 97.0643693
THC Std 2 - 0.167 mg/mL 0.1331 0.167 79.71044816
THC Std 3 - 0.25 mg/mL 0.1568 0.25 62.71320717















Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.323 5.81E+03 180 0.00097 180
 STD #2 0.016 2.316 8.58E+04 2691 0.0164 2691
 STD# 3 0.031 2.301 1.69E+05 5297 0.03242 5297
STD# 4 0.25 2.29 1.28E+06 40591 0.2493 40591
 STD# 5 0.5 2.288 2.19E+06 74853 0.45984 74853
40 10X 2.283 7.02E+05 22242 0.13654 22242 199.7 10 17.09313971
41 10X 2.285 3.41E+05 10902 0.06686 10902 199.9 10 8.36168084
42 10X 2.286 3.93E+05 12586 0.07721 12586 199.3 10 9.685148018
43 10X 2.307 4.01E+05 12838 0.07875 12838 200 10 9.84375
44 10X 2.287 4.42E+05 14099 0.08651 14099 200.7 10 10.77603388
45 10X 2.271 3.46E+05 10998 0.06745 10998 199.1 10 8.46936213
46 10X 2.274 5.90E+05 18794 0.11536 18794 199.6 10 14.4488978
47 10X 2.285 5.26E+05 16583 0.10177 16583 199.3 10 12.76593076
48 10X 2.267 6.16E+05 19566 0.1201 19566 199.6 10 15.04258517
49 10X 2.256 7.25E+05 23170 0.14225 23170 200.4 10 17.74575848
PRP1 2.26 4.69E+05 15087 0.09258 15087 199.1 10 11.62481165
1
PRP2 2.269 1.19E+05 3827 0.02338 3827 200.3 10 2.918122816
PRP3 2.266 2.13E+05 6799 0.04165 6799 200.3 10 5.198452322
PRP4 2.262 1.45E+05 4577 0.02799 4577 200.9 10 3.483076157








Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.29 5.57E+03 178 0.00097 178
 STD #2 0.016 2.323 8.20E+04 2620 0.0161 2620
 STD# 3 0.031 2.285 1.64E+05 5336 0.03294 5336
STD# 4 0.25 2.286 1.22E+06 40207 0.24905 40207
 STD# 5 0.5 2.285 2.12E+06 74431 0.46114 74431
40 10X 2.283 6.83E+05 21464 0.13289 21464 199.7 10 16.63620431
41 10X 2.338 3.37E+05 10361 0.06408 10361 199.9 10 8.014007004
42 10X 2.324 4.11E+05 12739 0.07882 12739 199.3 10 9.887104867
43 10X 2.32 3.86E+05 12017 0.07434 12017 200 10 9.2925
44 10X 2.379 4.11E+05 12847 0.07949 12847 200.7 10 9.90159442
45 10X 2.356 3.22E+05 10286 0.06361 10286 199.1 10 7.987192366
46 10X 2.359 5.52E+05 17706 0.1096 17706 199.6 10 13.72745491
47 10X 2.349 4.76E+05 15589 0.09648 15589 199.3 10 12.10235825
48 10X 2.323 5.67E+05 18532 0.11472 18532 199.6 10 14.36873747
49 10X 2.391 5.88E+05 19038 0.11786 19038 200.4 10 14.70309381
PRP1 2.382 3.96E+05 12919 0.07993 12919 199.1 10 10.03641386
PRP2 2.325 1.08E+05 3654 0.02252 3654 200.3 10 2.810783824
PRP3 2.311 1.84E+05 6315 0.039 6315 200.3 10 4.867698452
PRP4 2.345 1.29E+05 4453 0.02747 4453 200.9 10 3.418367347




TABLE 7A. LCMS Day 2 
 
 
Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.238 5.38E+03 180 0.00097 180
 STD #2 0.016 2.232 7.88E+04 2656 0.01631 2656
 STD# 3 0.031 2.237 1.56E+05 5289 0.03261 5289
STD# 4 0.25 2.234 1.17E+06 39919 0.24706 39919
 STD# 5 0.5 2.244 2.06E+06 74971 0.46412 74971
40 10X 2.299 6.39E+05 21889 0.1354 21889 199.7 10 16.9504256
41 10X 2.306 2.98E+05 10320 0.06376 10320 199.9 10 7.97398699
42 10X 2.292 3.44E+05 12130 0.07498 12130 199.3 10 9.40541897
43 10X 2.37 3.36E+05 11509 0.07113 11509 200 10 8.89125
44 10X 2.314 3.81E+05 13608 0.08413 13608 200.7 10 10.4795715
45 10X 2.293 2.82E+05 10337 0.06387 10337 199.1 10 8.01983928
46 10X 2.336 4.35E+05 15691 0.09703 15691 199.6 10 12.1530561
47 10X 2.334 3.84E+05 14174 0.08763 14174 199.3 10 10.9922228
48 10X 2.382 4.89E+05 18087 0.11186 18087 199.6 10 14.010521
49 10X 2.319 5.31E+05 19684 0.12175 19684 200.4 10 15.1883733
PRP1 2.338 3.58E+05 13436 0.08188 13436 199.1 10 10.2812657
PRP2 2.345 9.18E+04 3495 0.02121 3495 200.3 10 2.64727908
PRP3 2.383 1.43E+05 5487 0.03337 5487 200.3 10 4.1650025
PRP4 2.426 7.66E+04 2913 0.01766 2913 200.9 10 2.19761075




TABLE 7B. LCMS DAY 2 
 
 
Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.301 3.83E+03 178 0.00097 178
 STD #2 0.016 2.293 5.72E+04 2710 0.01642 2710
 STD# 3 0.031 2.292 1.12E+05 5321 0.03235 5321
STD# 4 0.25 2.295 8.59E+05 41039 0.25035 41039
 STD# 5 0.5 2.29 1.62E+06 79529 0.48526 79529
40 10X 2.286 4.65E+05 22358 0.13633 22358 199.7 10 17.0668503
41 10X 2.291 2.28E+05 10985 0.06693 10985 199.9 10 8.37043522
42 10X 2.291 2.64E+05 12730 0.07757 12730 199.3 10 9.73030607
43 10X 2.29 2.68E+05 12998 0.07921 12998 200 10 9.90125
44 10X 2.282 2.97E+05 14401 0.08777 14401 200.7 10 10.9329846
45 10X 2.282 2.29E+05 11106 0.06766 11106 199.1 10 8.49573079
46 10X 2.283 3.93E+05 19207 0.1171 19207 199.6 10 14.6668337
47 10X 2.278 3.49E+05 16912 0.1031 16912 199.3 10 12.9327647
48 10X 2.278 4.09E+05 19929 0.12151 19929 199.6 10 15.2191884
49 10X 2.277 4.82E+05 23500 0.14331 23500 200.4 10 17.877994
PRP1 2.279 3.17E+05 15395 0.09384 15395 199.1 10 11.7830236
PRP2 2.275 8.07E+04 3903 0.0237 3903 200.3 10 2.95806291
PRP3 2.28 1.42E+05 6915 0.04208 6915 200.3 10 5.25212182
PRP4 2.281 9.62E+04 4665 0.02835 4665 200.9 10 3.52787456









Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.3 4.16E+03 120 0.0008 120
 STD #2 0.016 2.293 6.15E+04 2705 0.0165 2705
 STD# 3 0.031 2.293 1.19E+05 5306 0.0323 5306
STD# 4 0.25 2.292 8.90E+05 40451 0.24583 40451
 STD# 5 0.5 2.293 1.66E+06 78060 0.47431 78060
40 10X 2.293 4.80E+05 22027 0.13389 22027 199.7 10 16.76139209
41 10X 2.286 2.37E+05 10854 0.06601 10854 199.9 10 8.255377689
42 10X 2.286 2.74E+05 12592 0.07657 12592 199.3 10 9.604867035
43 10X 2.292 2.76E+05 12611 0.07669 12611 200 10 9.58625
44 10X 2.291 3.02E+05 13860 0.08427 13860 200.7 10 10.49701046
45 10X 2.292 2.32E+05 10669 0.06489 10669 199.1 10 8.14791562
46 10X 2.29 3.97E+05 18299 0.11124 18299 199.6 10 13.93286573
47 10X 2.288 3.49E+05 16163 0.09827 16163 199.3 10 12.32689413
48 10X 2.273 4.09E+05 19054 0.11583 19054 199.6 10 14.50776553
49 10X 2.273 4.77E+05 22219 0.13506 22219 200.4 10 16.8488024
PRP1 2.273 3.16E+05 14587 0.08869 14587 199.1 10 11.13636364
PRP2 2.259 8.04E+04 3732 0.02275 3732 200.3 10 2.839490764
PRP3 2.259 1.44E+05 6703 0.04079 6703 200.3 10 5.09111333
PRP4 2.266 9.89E+04 4583 0.02791 4583 200.9 10 3.473120956









Sample RT Height Response mg/mL Area weight dilution THC % Conc.
STD #1 0.001 2.263 3.84E+03 177 0.00114 177
 STD #2 0.016 2.258 5.66E+04 2653 0.01619 2653
 STD# 3 0.031 2.261 1.12E+05 5222 0.0318 5222
STD# 4 0.25 2.258 8.35E+05 39783 0.24176 39783
 STD# 5 0.5 2.253 1.61E+06 79317 0.48195 79317
40 10X 2.253 4.76E+05 22649 0.13767 22649 199.7 10 17.2346019
41 10X 2.264 2.32E+05 11049 0.0672 11049 199.9 10 8.404202101
42 10X 2.265 2.68E+05 12833 0.07804 12833 199.3 10 9.789262418
43 10X 2.251 2.70E+05 12861 0.0782 12861 200 10 9.775
44 10X 2.249 2.99E+05 14280 0.08682 14280 200.7 10 10.81464873
45 10X 2.25 2.27E+05 10892 0.06624 10892 199.1 10 8.317428428
46 10X 2.253 4.00E+05 19050 0.1158 19050 199.6 10 14.50400802
47 10X 2.247 3.52E+05 16809 0.10219 16809 199.3 10 12.81861515
48 10X 2.238 4.14E+05 19918 0.12108 19918 199.6 10 15.16533066
49 10X 2.237 4.83E+05 23512 0.14291 23512 200.4 10 17.82809381
PRP1 2.242 3.12E+05 15103 0.09183 15103 199.1 10 11.53063787
PRP2 2.245 8.07E+04 3846 0.02344 3846 200.3 10 2.925611583
PRP3 2.249 1.41E+05 6723 0.04091 6723 200.3 10 5.106090864
PRP4 2.243 9.58E+04 4607 0.02806 4607 200.9 10 3.491786959
































df SS MS F Significance F
Regression 1 1.36933E+12 1.36933E+12 25.1358428 0.015278512
Residual 3 1.63431E+11 54476995496
Total 4 1.53276E+12
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept -362083.638 216063.6451 -1.675819354 0.19236697 -1049694.587 325527.311 -1049694.587 325527.3109
































df SS MS F Significance F
Regression 1 4229947671 4229947671 19619076650 8.03E-16
Residual 3 0.646811429 0.21560381
Total 4 4229947671
Coefficients Standard Error t Stat P-value Lower 95%Upper 95%Lower 95.0%Upper 95.0%
Intercept 21.83503384 0.272431567 80.1486922 4.28093E-06 20.96804 22.70203 20.96804 22.70203
X Variable 1 162732.8276 1.161812082 140068.114 8.02515E-16 162729.1 162736.5 162729.1 162736.5
SE of intercept 0.272431567


























40 16.96 0.0043 0.0120
41 8.23 0.0181 0.0211
42 9.68 0.0120 0.0156
43 9.55 0.0308 0.0373
44 10.57 0.0261 0.0322
45 8.24 0.0159 0.0245
46 13.91 0.0331 0.0611
47 12.32 0.0294 0.0538
48 14.72 0.0140 0.0307
49 16.70 0.0140 0.0307
PRP 1 11.07 0.0414 0.0609
PRP 2 2.85 0.0198 0.0365
PRP 3 4.95 0.0490 0.0747
PRP 4 3.27 0.0798 0.1466


























































































































































































































































































































































































































































FIGURE 28. Resin Left Behind in the Grinding Step 
 
